MINNEAPOLIS HEART INSTITUTE

Phase 3 Trial Shows Stem Cell Therapy Reduces Heart Failure Risk by 57% After Heart Attack

- The PREVENT-TAHA8 phase 3 trial demonstrated that intracoronary infusion of mesenchymal stem cells derived from Wharton's jelly significantly reduced heart failure incidence by 57% in STEMI patients. - At 3 years follow-up, only 5.74% of stem cell-treated patients developed heart failure compared to 16.08% in the standard care group. - The treatment also improved left ventricular ejection fraction by approximately 6% more than standard care and reduced heart failure readmissions by 78%. - Researchers attribute the benefits to the anti-inflammatory properties of mesenchymal stem cells, positioning this therapy as a viable adjunctive treatment for post-MI cardiac protection.